Design, insilico modelling and functionality theory of folate receptor targeted Myricetin -loaded bovine serum albumin nanoparticle formulation for cancer treatment.
Targeted drug delivery systems are promising field of research. Nano-engineered material-mediated drug delivery possess remarkable potential for the treatment of various malignancies. Here, a folic acid (FA) conjugated bovine serum albumin (BSA) nanoparticles (NPs) were used to encapsulate myricetin (Myr). Subsequently, the delivery of Myr via naturally overexpressed folate receptor (FR) to FR-positive cancer breast cells was studied. Myr-loaded BSA NPs were assembled by modified desolvation cross-linking technique. FA conjugated carrier, N-hydroxysuccinimde (NHS)-FA ester, was successfully synthesized. Its functional and structural characteristics were confirmed by UV, FT-IR, and proton NMR. The biocompatible FA conjugated, Myr-loaded BSA NPs (FA-Myr-BSA NPs) were successfully formulated using carbonate/bicarbonate buffer. Their morphology, size, shape, physiological stability, and drug release kinetics were studied. The molecular docking studies revealed that FA-Myr-BSA NPs readily non-covalently bind to folate receptor and facilitate active drug endocytosis. FA-Myr-BSA NPs can trigger fast release of Myr in acidic medium (pH 5.4), and showed high biocompatibility in physiological medium. FA-Myr-BSA NPs effectively decrease the viability of MCF-7 cells after 24 h with 72.45 µg/mL IC50 value. In addition, FA-Myr-BSA NPs enhanced the uptake of Myr in MCF-7 cells. After incubation typical apoptotic morphology of condensed nuclei and distorted membrane bodies was observed. Additionally, NPs also targeted mitochondria of MCF-7 cells and significantly increase the ROS release and contribute to the loss of mitochondrial membrane integrity. The observed results confirm that newly-developed FA-Myr-BSA NPs can serve as a potential carrier for Myr to increase anticancer activity of this chemotherapeutic.